POM-V Prescription Required

Suxilon 1.5g Granules for Top Dressing

Active ingredient: Suxibuzone

Form

Powder

Species

Horses

Manufacturer

Ecuphar Veterinaria S.L.U.

VMD MA No.

46037/4001

What it's used for

Treatment of pain and inflammation associated with musculo-skeletal conditions in the horse

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Suxibuzone

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Suxilon 1.5g Granules for Top Dressing — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Treatment of pain and inflammation associated with musculo-skeletal conditions in
the horse

When added to a portion of feed the product will be accepted by most horses.
The following should be used as a guide, according to individual response:
Horses
For a 480 kg bodyweight horse, the contents of 2 sachets should be administered twice
daily (equivalent to 12.5 mg of suxibuzone/kg/day) for 2 days, followed by 1 sachet twice
daily (6.25 mg of suxibuzone/kg/day) for 3 days.
Thereafter, 1 sachet daily (3.1 mg of suxibuzone/kg/day) or on alternate days, or the
minimum dose necessary for a satisfactory clinical response.
AN: 03418/2024 & 03419/2024
Ponies (breeds of less than 149 cm high at the withers when full grown)
Ponies should receive only half the dose rate recommended for horses.
For a 240 kg bodyweight pony, the contents of 1 sachet should be administered daily
(equivalent to 6.25 mg of suxibuzone/kg/day) for 2 days, followed by 1/2 sachet daily (3.1
mg of suxibuzone/kg/day) for 3 days or 1 sachet on alternate days.
Thereafter, reduce the dose to the minimum dose necessary for a satisfactory clinical
response.
For administration of less than one sachet, use the measuring scoop provided. One full
level scoop contains 5 g granules (equivalent to 1/2 sachet) and up to the green line level
contains 2,5 g granules (equivalent to 1/4 sachet).
Hay, as part of the diet, may delay the absorption of suxibuzone and so the onset of
clinical effect. It is advisable not to feed hay immediately prior to, or with this medicinal
product.
See also section 3.4 Special warnings.
If no clinical response is evident after 4-5 days, discontinue treatment and reconsider the
diagnosis.

Do not use in animals with renal, hepatic or cardiac disorders.
AN: 03418/2024 & 03419/2024
Do not use in animals where there is the possibility of gastro-intestinal ulceration or
bleeding. Do not use in animals where there is evidence of a blood dyscrasia.
Do not use in cases of known hypersensitivity to the active substance or any of the
excipients.

After continued use, or at high doses gastro-intestinal changes may occur. Occasionally
blood dyscrasias and renal alterations may be found, especially in animals with restricted
access to water.
AN: 03418/2024 & 03419/2024
Horses, ponies:
Undetermined frequency (cannot be
estimated from the available data)
Digestive tract disorder
Renal alteration
Blood dyscrasia
Blood dyscrasia
Hepatic disorder
1
after continuous use or at high doses
especially in animals with restricted access to water
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details.

NSAIDs can cause inhibition of phagocytosis and hence, in the treatment of inflammatory
conditions associated with bacterial infections appropriate antimicrobial therapy should be
instigated.

Special precautions for safe use in the target species:
Do not exceed the stated dose or duration of treatment. Dosage should be kept to a
minimum for alleviation of symptoms.
During treatment of very young animals (less than 12 weeks) where development of their
hepatic or renal function may be incomplete, or in aged animals which may have these
functions impaired, as well as in ponies, additional risk may be involved. In these cases,
doses should be accurately calculated and patients monitored closely.
During treatment, do not restrict the consumption of water. Avoid use in any dehydrated,
hypovolaemic or hypotensive animals as there may be an increased risk of renal failure.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Wear suitable gloves. Wash hands after use.
Use in a well-ventilated area. Avoid inhaling any dust when opening sachet and mixing
with feed. In case of accidental contact with eyes, wash immediately with plenty of clean
water. In case of accidental ingestion, seek medical advice immediately and show the
package leaflet to the physician.
Special precautions for the protection of the environment:
Not applicable.

Suxibuzone and its metabolites may be highly bound to plasma proteins and compete with
other highly bound drugs eg sulphonamides, warfarin; or it may itself be displaced to
produce an increase of non-bound pharmacologically active concentrations which could
lead to toxic effects. Drug compatibility must be closely monitored when adjunctive therapy
is required.
Do not administer together with other NSAIDs concurrently or within 24 hours of each
other.
Concurrent administration of potentially nephrotoxic drugs should be avoided.

After opening a sachet re-seal as well as possible between doses.
This veterinary medicinal product does not require any special storage conditions.

Not to be used in horses intended for human consumption.
Treated horses may never be slaughtered for human consumption.
AN: 03418/2024 & 03419/2024
The horse must have been declared as not intended for human consumption under
national horse passport legislation.
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.